Burst Diagnostics Inc.
Fort Collins, CO
- UEI
- MJNAWSUKTH68
- CAGE
- 9VE13, 8YED8
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 308 E Vine Dr #104, Fort Collins, CO 80524, USA
- Website
- burst-dx.com
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Colorado State University | W911QY2120003 | $65,000 | |
| Emory University | U54EB027690 | $50,000 |
Similar vendors
About the company
Burst Diagnostics Inc., a Fort Collins, Colorado-based for-profit organization, develops point-of-care and at-home diagnostic devices and operates as both a federal grant recipient (50% of recent awards) and a sub-recipient on university-managed research grants (50% of recent awards). The vendor does not hold federal contracts; its federal footprint consists entirely of small research grants and sub-awards from the National Institutes of Health and the Army Research Development and Engineering Command, with a combined obligated value of $975 thousand across four awards since 2023.
Burst's grant portfolio spans three NIH institutes and one Army customer. The National Institute of Child Health and Human Development funded a $301,299 project grant awarded September 15, 2025, and completing August 31, 2026, in partnership with FemmeLoop to develop a multiplexed, quantitative point-of-care and at-home hormone diagnostic measuring estradiol, progesterone, luteinizing hormone, and follicle-stimulating hormone in blood and saliva samples to enable determination of perimenopause and menopause status and personalization of hormone replacement therapy. The National Institute of Allergy and Infectious Diseases funded a $301,299 project grant awarded August 1, 2023, and completed July 31, 2024, for development of an ultrasensitive rapid strep test for Group A Streptococcus detection at point-of-care and at-home settings, designed to reduce unnecessary antibiotic treatment in children. As a sub-recipient, Burst performs work under Colorado State University on a March 2026 award for colorimetric water quality sensors (housing design, fabrication, and production runs of 300 to 1,000 three-analyte devices) and under Emory University on an October 2025 sub-award related to the Atlanta Center for Microsystems Engineered Point-of-Care Technologies. Recent awards show two grants in 2025 and one in 2026; one award faces completion within the next twenty-four months.
Quick answers
Is Burst Diagnostics Inc. registered in SAM.gov?
Yes. Burst Diagnostics Inc.'s SAM.gov registration is active through January 29, 2027.
What is Burst Diagnostics Inc.'s most recent federal award?
Burst Diagnostics Inc.'s most recent federal grant award is Multiplexed hormone test for personalizing menopause treatment (R43HD116666), from National Institute of Child Health and Human Development (NIH), on September 15, 2025.
On GovTribe
See Burst Diagnostics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors